生物股份(600201) - 2021 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 40.41% to CNY 211,332,445.68 year-on-year[11] - Operating revenue rose by 41.85% to CNY 519,424,062.86 compared to the same period last year[11] - Basic earnings per share increased by 46.15% to CNY 0.19 compared to the same period last year[11] - Total profit increased by 7,007,000 yuan, a growth of 38.50%, attributed to the rise in operating income[22] - The company's net profit for Q1 2021 was CNY 217,204,002.03, an increase of 37% compared to CNY 158,601,855.20 in Q1 2020[76] - The total comprehensive income for Q1 2021 was CNY 217,243,898.23, compared to CNY 158,651,560.98 in Q1 2020[78] Revenue and Costs - Total operating revenue for Q1 2021 reached RMB 519,424,062.86, a significant increase of 41.8% compared to RMB 366,175,089.52 in Q1 2020[72] - Total operating costs for Q1 2021 were RMB 272,001,358.64, up 48.3% from RMB 183,471,337.15 in Q1 2020[72] - Cash received from sales of goods and services increased by 10,414,000 yuan, up 47.48%, due to higher market-oriented vaccine sales[24] - Cash paid for purchasing goods and services increased by 6,811,000 yuan, a rise of 87.62%, reflecting higher raw material expenditures[24] Assets and Liabilities - Total assets increased by 3.16% to CNY 6,476,415,520.78 compared to the end of the previous year[11] - Total liabilities as of March 31, 2021, were RMB 309,724,888.39, a decrease from RMB 315,107,889.15 at the end of 2020[70] - The total equity attributable to shareholders increased to RMB 5,200,810,998.43 as of March 31, 2021, from RMB 4,981,663,905.19 at the end of 2020[55] Cash Flow - Net cash flow from operating activities decreased by 45.71% to CNY 27,069,382.49 compared to the previous year[11] - Cash inflow from operating activities totaled ¥360,859,864.96, an increase from ¥262,252,461.54 in the previous period, representing a growth of approximately 37.6%[86] - Cash outflow from operating activities was ¥333,790,482.47, compared to ¥212,393,144.93 previously, indicating a rise of about 57.1%[86] - Cash and cash equivalents at the end of the period stood at ¥1,236,675,331.77, a decrease from ¥1,273,110,964.79[88] Shareholder Information - The total number of shareholders reached 55,256 by the end of the reporting period[17] - The largest shareholder, Hong Kong Central Clearing Limited, holds 18.20% of the shares[17] Research and Development - Research and development expenses for Q1 2021 were RMB 29,028,789.46, up from RMB 22,536,657.41 in Q1 2020, indicating a focus on innovation[72] Future Plans - The company plans to continue expanding its market presence and invest in new product development[11] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[72]